Nephroprotective properties of glucose-lowering drugs
- Authors: Pokrovskaya E.V.1, Trubitsyna N.P.1, Zaytseva N.V.1
-
Affiliations:
- Endocrinology Research Centre
- Issue: Vol 21, No 4 (2019)
- Pages: 35-39
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/96814
- DOI: https://doi.org/10.26442/20751753.2019.4.190332
- ID: 96814
Cite item
Full Text
Abstract
Diabetic nephropathy is one of microvascular complications of diabetes mellitus, which is the leading cause of end-stage renal disease, requiring renal replacement therapy (dialysis, kidney transplantation). The quality and life expectancy of patients on dialysis is very low, and treatment requires significant material costs, therefore, a high priority is accorded to the prevention of the development and the progression of diabetic nephropathy. Primary prophylaxis is aimed at maintaining the target level of glycemia and glycated hemoglobin, blood pressure, lipid spectrum, for the secondary prevention, in addition to the above-mentioned indicators, drugs from RAAS blockers group are used. Also, in recent years, several classes of new glucose-lowering drugs (iSGLT-2, aGLP-1, iDPP-4) have appeared, affecting not only glycemia and metabolic parameters, but also renal function. In this review, we analyzed the results of large-scale international randomized trials designed to assess the nephroprotective properties of glucose-lowering drugs from the iSGLT-2, aGLP-1 and iDPP-4 groups. In studies with iSGLT-2 group, it is possible to speak of a class effect on the reduction of cardiovascular and renal risks and recommend their use for proven CVD and CKD. In the group of incretin drugs, one may infer, that they are cardiovascular safe, and in some studies, a positive effect on renal function in the form of reduced AU has been shown. Based on the data obtained, there is great interest in the study of the direct nephroprotective effect of these drugs, which may have a fundamental role in preventing the development and the progression of diabetic nephropathy.
Full Text
##article.viewOnOriginalSite##About the authors
Elena V. Pokrovskaya
Endocrinology Research Centre
Email: pokrovskaya.93@mail.ru
Clinical Resident Moscow, Russia
Natalia P. Trubitsyna
Endocrinology Research Centre
Email: trubicina@mail.ru
канд. мед. наук, вед. науч. сотр. Moscow, Russia
Natalia V. Zaytseva
Endocrinology Research Centre
Email: nata.zaec@gmail.com
Cand. Sci. (Med.) Moscow, Russia
References
- Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический отчет по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017; 20 (1): 13-41. doi: 10.14341/DM8664
- Cho N.H, Shaw J.E, Karuranga S et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045/2018; 138: 271-81. doi: 10.1016/j.diabres.2018.02.023
- Fioretto P, Zambon A, Rossato M et al. SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care 2016; 39 (2): 165-71. doi: 10.2337/dcS15-3006
- Modafferi S, Ries M, Calabrese V et al. Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis. Diabetes Ther 2019; 10 (1): 229-43.
- Шамхалова М.Ш., Викулова О.К., Железнякова А.В. и др. Эпидемиология хронической болезни почек в Российской Федерации по данным Федерального регистра взрослых пациентов с сахарным диабетом (2013-2016 гг.). Сахарный диабет. 2018; 21 (3): 160-9. doi: 10.14341/DM9687
- Prischl F.C, Wanner C. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. Kidney Int Rep 2018; 3 (5): 1030-8. doi: 10.1016/j.ekir.2018.04.008
- Górriz J.L, Nieto J, Navarro-González J.F et al. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med 2015; 4 (10): 1866-89. doi: 10.3390/jcm4101866
- Levin A, Stevens P.E, Bilous R.W et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter (Suppl.) 2013; 3 (1): 1-150. doi: 10.1038/kisup.2012.73
- Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я. и др. Клинические рекомендации по диагностике, скринингу, профилактике и лечению хронической болезни почек у больных сахарным диабетом. 2014. https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pohki.pdf
- Penno G, Garofolo M, Del Prato S. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutrit, Metab Cardiovasc Dis 2016; 26 (5): 361-73. doi: 10.1016/j.numecd.2016.01.001
- Байрашева В.К., Бабенко А.Ю., Байрамов А.А. и др. Перспективы нефропротекции при сахарном диабете 2-го типа с использованием ингибитора ДПП-4 вилдаглиптина. Мед. совет. 2017; 3: 8-16. doi: 10.21518/2079-701X-2017-3-8-16
- Davies M.J, D'Alessio D.A, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61 (12): 2461-98. doi: 10.1007/s00125-018-4729-5
- Moses R.G, Colagiuri S, Pollock C. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. Australas Med J 2014; 7 (10): 405-15. doi: 10.4066/AMJ.2014.2181
- Шестакова М.В., Сухарева О.Ю. Глифлозины: особенности сахароснижающего действия и негликемические эффекты нового класса препаратов. Клин. фармакология и терапия. 2016; 25 (2): 65-71.
- Dekkers C.C.J, Gansevoort R.T, Heerspink H.J.L. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Curr Diab Rep 2018; 18 (5): 27. doi: 10.1007/s11892-018-0992-6
- Корбут А.И., Климонтов В.В. Эмпаглифлозин: новая стратегия нефропротекции при сахарном диабете. Сахарный диабет. 2017; 20 (1): 75-84. doi: 10.14341/DM8005
- Heerspink Hiddo J.L, Kosiborod М, Inzucchi Silvio E et al. Kidney International. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018; 94 (1): 26-39. doi: 10.1016/j.kint.2017.12.027
- Yehya A, Sadhu A.R. New Therapeutic Strategies for Type 2 Diabetes. Methodist Debakey Cardiovasc J 2018; 14 (4): 281-8. doi: 10.14797/mdcj-14-4-281
- Alicic R.Z, Johnson E.J, and Tuttle K.R. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. J Kidney Dis 2017; 72 (2): 267-77. doi: 10.1053/j.ajkd.2018.03.022
- Mahaffey K.W, Neal B, Perkovic V et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018; 137 (4): 323-34. doi: 10.1161/CIRCULATIONAHA.117.032038
- Jakher H, Chang T.I, Tan M, Mahaffey K.W. Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes 2019; 12: 209-15. doi: 10.2147/DMSO.S184437
- Herrington W.G, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J 2018; 11 (6): 749-61. doi: 10.1093/ckj/sfy090
- Jardine M.J, Mahaffey K.W, Neal B et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol 2017; 46 (6): 462-72. doi: 10.1159/000484633
- Wiviott S.D, Raz I, Bonaca M.P et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380 (4): 347-57. doi: 10.1056/NEJMoa1812389
- Zelniker T.A, Wiviott S.D, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31-9. doi: 10.1016/S0140-6736 (18)32590-X
- Standl E, Schnell O, McGuire D.K et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabet Endocrinol 2017; (5): 391-402. doi: 10.1016/s2213-8587 (17)30033-5
- Lim S, Kim K.M, Nauck M.A. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. Trends Endocrinol Metab 2018; 29 (4): 238-48. doi: 10.1016/j.tem.2018.01.011
- Marso S.P, Daniels G.H, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-22. doi: 10.1056/NEJMoa1603827
- Prischl F.C, Wanner C. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. Kidney Int Rep 2018; 3 (5): 1030-8. doi: 10.1016/j.ekir.2018.04.008
- Dey A.K, Groenendyk J, Mehta N.N, Gourgari E. The Effect of SGLT-2 inhibitors and GLP-1 Agonists on Cardiovascular Disease in Patients with Type 2 Diabetes. Clin Cardiol 2019; 42 (3): 406-12. doi: 10.1002/clc.23152
- Hernandez A.F, Green J.B, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392 (10157): 1519-29. doi: 10.1016/s0140-6736 (18)32261-x
- Fioretto P, Frascati A. Role of incretin based therapies in the treatment of diabetic kidney disease. Diabetes Mellitus 2018; 21 (5): 395-8. doi: 10.14341/DM9845
- Schnell O, Standl E, Catrinoiu D et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol 2016; 15: 33. doi: 10.1186/s12933-016-0357-x